adtecplasma-blog

[adtecplasma-blog]

Adtec Plasma in CSP Renewable Energy Project

Adtec Europe Ltd is sponsoring two post-graduate students to do research in new potential applications for plasma in collaboration with Cranfield University.

The focus of this research is to understand the utilisation of plasma-assisted surface conditioning of low-iron glass solar reflecting mirrors for concentrating solar thermal power applications. The research project is supervised by leading experts in this field Professor Chris Sansom and Dr Peter King of Cranfield University and Dr Adam Bennett of Cranfield Plasma Solutions.

CSP plants generate electricity by concentrating sun light with large arrays of mirrors which are usually located in desert regions. Consequently, the mirrors get covered in sand and dust, and require cleaning with brushes and water on a regular basis. Currently much water is used to clean the mirrors, a precious resource in arid terrains. The aim of this project is to investigate the characteristics of a novel atmospheric pressure plasma system used to condition CSP concentrating mirrors which will be capable of reducing the amount of water used in the cleaning process.

The Global Concentrating Solar Power (CSP) market was valued at over $3 Billion US in 2016 and is anticipated to grow by 13% by 2025. There is also a compelling business desire to undertake this project. The development of a novel atmospheric pressure plasma system will be a significant game changer in the CSP market. Such a disruptive technology is anticipated to yield significant commercial benefits.

[adtecplasma-blog]

New Corporate Management Team at Adtec.

Adtec Europe is happy to announce a new President at our parent company Adtec Plasma Technology Co., Ltd Japan (listed on TSE 6668) - Mr Hidenori Morishita. Mr Morishita has been working at Adtec Japan for over 15 years primarily in the role of business development. 

We look forward to working together with the new Corporate Management Team including Adtec Europe Managing Director Mary McGovern to develop the RF and Plasma business worldwide.  

The former president Mr Shuitsu Fujii founded Adtec Plasma Technology in 1985 and he will continue to be actively involved in guiding the company in his new role as Executive Chairman. 

Adtec has been supplying reliable RF plasma solutions to the semiconductor and display industries worldwide for over 30 years. 

Atmospheric pressure cold plasma technology was also first developed at the Innovation Centre in Adtec Japan. This technology is now commercialized by Adtec Europe for medical and surface treatment applications in collaboration with our parent company. 

[adtecplasma-blog]

Adtec Europe Ltd introduces new Actinic Keratoses Clinical Trial Results at the European Academy of Dermatology and Venerology Annual Meeting in Paris.

P0736 – Efficacy of cold atmospheric plasma versus diclofenac 3% gel in patients with actinic keratoses/field cancerization: preliminary results of a prospective, randomized, rater-blinded study (ACTICAP).

Actinic Keratoses (AK) represent the most common skin malignancy worldwide and are considered the earliest stage of squamous cell carcinoma (SCC). Importantly, up to 20% of AK transform into invasive SCC within 10-25 years.

Conventional treatments for AK and field cancerization bear significant side effects and/or are restricted to small skin areas. Thus, there is a continuing need for effective as well as non-toxic lesion and field-directed therapies for AK.

Results to be presented include data from 34 study subjects. After the final treatment, the total number of AK within the CAP-treated areas was reduced on average by 45% versus 22% within the diclofenac-treated areas. Similarly, the surface area affected by AK decreased by 47% (CAP) as compared to 32%(diclofenac). There were no CAP related adverse effects.

The conclusions are that CAP is a safe as well as effective tool for the treatment of AK and field cancerization. It might be especially beneficial for patients in whom non-toxic treatment options are preferable, such as immunosuppressed individuals. The skin rejuvenating effects of CAP observed in the trial deserve further exploration.

Adtec’s SteriPlas plasma medical device covers a treatment area of 12cm2 in 2 minutes. Gas Plasma has proven clinical efficacy in the management of wound and surgical site infections. The treatment is painless  with no side effects or adverse events reported over 10 years of use.

[adtecplasma-blog]

Leeds Teaching Hospitals NHS Trust joins as a trial centre for current RCT

Adtec Healthcare is excited to announce that Leeds Teaching Hospitals NHS Trust will be joining as a trial centre for our randomised controlled trial to evaluate the efficacy of non-thermal gas plasma on sub-clinical wound infection (biofilm) in patients with diabetic foot ulcers compared to those treated with standard care of dressings. The clinical team will be led by our clinical partners, Mr David Russell, the Podiatry and Vascular Research Teams in the Diabetes Limb Salvage Service at Leeds Teaching Hospitals. The Chief Investigator for the trial is Professor Steven Jeffery from HM Forces, Queen Elizabeth Hospital.

 Biofilms in wounds are considered to be one of the major challenges in infection management. They are associated with 65-80% of all non-healing wounds leading to chronic inflammation and delayed healing. 1

Bacteria produced within biofilm are up to 1000 times more resistant to antibiotics which severely complicates treatment options. 2

 Debridement is one of the most important treatment strategies against biofilm but does not remove all biofilm and cannot be used alone. Biofilms can reform rapidly. Appropriate topical antiseptic applications within this time-dependent window can suppress biofilm reformation. 3

 The hypothesis to be tested is that the healing of chronic diabetic foot ulcers that are stalled by biofilm can be accelerated following intervention with the Adtec SteriPlas.

 The secondary objective is to correlate clinical presentation of long standing wounds as recorded through digital photographs in terms of wound volume/wound dimensions with wound microbiology (number of bacterial species present), biochemistry and histology in a series of diabetic foot ulcers.

 Recruited patients will be randomly selected to either receive standard care of dressings or two sessions of gas plasma treatment each week for a total of 4 weeks.

 The Adtec SteriPlas is a CE marked medical device with proven efficacy in infection management of ulcers/surgical site infections and treatment of some skin diseases. It operates with a physical mode of action, meaning that bacteria developing a primary or secondary resistance to plasma is unlikely. 4

 Previous clinical trials that we have conducted and patient treatments in hospitals have shown that the Adtec SteriPlas:

 · Is 50% more effective than antibiotics. 5

· Offers a 73% reduction in bacterial load despite the type of bacteria or its resistance to antibiotics. 5

· Is proven to kill a wide range of microorganisms including fungal, viral, yeast and bacterial superinfections in both Gram-negative and Gram-positive.

 For more information about the Adtec SteriPlas, visit our website www.adtecplasma.com or email us at info@adtec.eu.com

 1. James et al, 2008; Percival and Bowler, 2008

2. Environ Health Perspect. 2010 Jul; 118 (7): A 228

3. Consensus guidelines for the identification and treatment of biofilms in chronic non-healing wounds, G. Shultz, T. Bjarnsholt, G. A. James, D. J. Leaper, A. McBain, M. Malone, P. Stoodley, T. Swanson, M. Tachi, R. Wolcott; for the Global Wound Biofilm Expert Panel

4. Plasma applications in medicine with a special focus on Dermatology, J. Heinlin, G. Isbary, W, Stolz, JEADV 2010.

5. Isbary et al, BJD Online 2012

[adtecplasma-blog]

Adtec Healthcare to exhibit at EWMA

We are excited to be exhibiting at this year’s EWMA2018 in Krakow May 9th-11th. 

You can find us at booth number W114 where we will of course have our SteriPlas medical device on display, ready to give a live demonstration on how a quick 2-minute application is enough to deactivate microrganisms including antibiotic resistant bacteria. 

Some gas plasma technology clinical results to be presented at the EWMA conference include  1 oral presentation and 3 poster presentations. 

 Dr Finja Jockenhöfer will be presenting on PLASMA THERAPY - ONCE A WEEK ENOUGH? PROSPECTIVE RCT TO VALIDATE THE INTERVAL OF PLASMA TREATMENT FOR REDUCTION OF WOUND AREA, BACTERIAL LOAD AND PAIN in  the free paper session: Quality of life 

Dr Heinrich Rotering will have a presentation on REMOVE IT OR TREAT IT- NEW TECHNOLOGIES FOR COMPLICATED WOUNDS.

Dr Joanne McCardle, Mrs Samantha Haycocks, Dr Paul Chadwick will have a presentation on A PROOF OF CONCEPT EVALUATION OF THE EFFICACY OF NON-THERMAL GAS PLASMA IN THE TREATMENT OF DIABETIC FOOT ULCERS THAT ARE STALLED BY SUB CLINICAL WOUND INFECTION in the E-Poster category: Diabetic Foot

Mr Keith Cutting will have a presentations on _ THE IMPACT OF ARGON PLASMA ON BACTERIAL PATHOGENS IN VITRO AND IN AN ANIMAL MODEL in the E-Poster category: Antimicrobials

For more information or to arrange a meeting with us during EWMA, please contact us at info@adtec.eu.com

www.ewma.org 

[adtecplasma-blog]

Innovation Award for SteriPlas Plasma Technology.

Adtec Healthcare congratulates Dr Rotering on his receipt of  the runner up Innovation award at the European Association for Cardio-Thoracic Surgery (EACTS) conference in Vienna on October 7th 2017..

Dr Rotering a Cardiac Surgeon at a University Hospital in Germany has pioneered the combination of Adtec SteriPlas technology and Negative Pressure Wound Management technology for the infection management of surgical site infections.  Dr Rotering and his colleagues have used Adtec gas plasma technology to successfully treat LVAD, Sternum and other surgical site infections. Dr Rotering will also present his most recent results at the EACTS conference on Monday 9th October.

Adtec SteriPlas cold plasma technology has proven efficacy in treatment of a wide range of infections. With a physical mode of action, gas plasma is unlikely to induce microbial resistance and can therefore be considered a viable alternative to antibiotics. Plasma (ionized gas) is a painless 2 minute topical antimicrobial treatment with no side effects or adverse events reported over 10 years of use.

[adtecplasma-blog]

Adtec Healthcare reports new case studies on the successful treatment of long-term chronic ulcers.

Adtec Healthcare reports the successful wound management of patients with long term chronic ulcers at 2 hospitals in Germany and Switzerland. Some of these results are included in case studies on the website. The patients had been suffering from long term chronic ulcers where all other treatments had failed. Treatment with Adtec SteriPlas gas plasma managed the infection and the ulcers progressed to complete healing. Following these encouraging case studies results, it is necessary to do a randomized controlled clinical trial to prove the clinical efficacy and benefits.

A chronic wound (ulcer) is an ulcer that does not heal within 3 months and is stalled at one stage. Some patients may have a chronic ulcer for a year or longer. We believe Adtec SteriPlas technology has the potential to not only enable the healing of chronic wounds that are stalled by sub-clinical wound infection (biofilm) but accelerate healing time following intervention with our non-thermal gas plasma.

We are conducting a randomized controlled clinical trial in collaboration with Salford Royal NHS Foundation Trust UK. The primary objective of this project is to evaluate the efficacy of Adtec SteriPlas on sub-clinical wound infection (biofilm) in patients with diabetic foot ulcers (DFU) compared to those treated with standard care dressings. The secondary objective is to correlate the clinical presentation of long standing DFUs with wound microbiology, biochemistry and histology. The efficacy in treatment of DFUs may be correlated to all types of chronic ulcers.

Adtec SteriPlas is a gas plasma medical device delivering active agents in plasma to the surface of the wound to manage the infection. Gas plasma has proven efficacy in the reduction of bacterial loads In wounds and can be considered as an alternative treatment to antibiotics. www.adtecplasma.com/clinical

[adtecplasma-blog]

Clinical Trial to investigate the potential benefits of treating Actinic Keratosis with Adtec SteriPlas  plasma technology.

Adtec Europe today announces the launch of a clinical trial to evaluate the change of the cutaneous microbiome in correlation to the efficacy of SteriPlas plasma technology compared to standard treatments on patients with Actinic Keratosis.

The clinical trial will be led by our clinical partners University Hospital Essen in Germany and Professor Dr Alexander Roesch is the Chief Investigator.

The clinical trial follows positive observations made in a series of patients with actinic keratosis at University Hospital Essen in 2016 and these results will soon be published in the Journal of the European Academy of Dermatology and Venereology.

The case series provided encouraging results leading to collaboration to do a clinical trial investigating the potential benefits and efficacy of plasma on Actinic Keratosis.

According to Professor Roesch ‘In the case series, all treated lesions responded to plasma treatment with some showing complete clinical clearance after seven treatments. No side effects including inflammation or pain were recorded. Therefore, plasma might represent a novel, safe treatment method for AK that is worth being further investigated in prospective trials concerning application schemes and its exact biological effects’  

The clinical trial is scheduled to begin in August 2017.

Adtec SteriPlas is a CE marked medical device with proven efficacy in infection management of ulcers/surgical site infections and treatment of some skin diseases.

AK is the most frequent epidermal neoplasia that occurs in fair-skinned people with increased cumulative exposure to UV-radiation. In 2005, AK affected more than 58 million people in the U.S.A. with a reported prevalence of 11-26% according to recent reports 1.

1.      Chetty P, Choi F, Mitchell T. Primary care review of actinic keratosis and its therapeutic options: a global perspective. Dermatol Ther (Heidelb) 2015; 5: 19-35.

[adtecplasma-blog]

Adtec Europe will exhibit at two events in 2017 showcasing our atmospheric pressure gas plasma technology for surface treatment applications in precision engineering

Potential applications of plasma treatment include

·         Surface cleaning

·         Surface modification

·         Surface Activation

·         Removal of organic contamination

 We believe that plasma technology has many potential uses in advanced engineering and we look forward to collaborating with experts in plastic and metal manufacturing.

 We will exhibit at the following events.

 31ST INTERNATIONAL CONFERENCE ON SURFACE MODIFICATION TECHNOLOGIES

SMT 31 - July 05-07, 2017 - University of Mons, Belgium

https://portail.umons.ac.be/FR/UNIVERSITE/ADMIN/CERP/CONGRES_COLLOQUES/Pages/05au07juillet2017-SMT31.aspx

 InterPlas 2017   26 - 28 SEPTEMBER 2017 NEC, BIRMINGHAM, UK

UK’s leading Plastics Industry event

http://www.interplasuk.com/

[adtecplasma-blog]

Adtec  introduces the plasma product portfolio designed and manufactured  in the UK by Adtec Europe Limited

Plasma processing is a material processing technology that is utilized to modify the chemical and physical properties of a surface. Plasma processing is most often in vacuum plasma chambers widely used in the semiconductor and display industries to meet the critical engineering requirements of high-tech industries.

At Adtec, we specialize in microwave driven atmospheric pressure gas plasma technology. Plasma, as an energized gas has a myriad of potential applications including preparing a surface to enhance precision engineering, cleaning and antimicrobial applications. Adtec’s plasma technology was first developed in the innovation department of our parent company Adtec Plasma Technology in Japan. With plasma expertise and engineering know-how developed in collaboration with our parent company, Adtec Europe can now offer customized solutions to our customers.

Photo Courtesy of TWI 

Gas Plasma applications include:

Antimicrobial – we have developed a gas plasma medical device (SteriPlas) in collaboration with the Max Planck Institute in Germany. SteriPlas is adopted as a topical antimicrobial in management of wound and surgical site infections in European hospitals. Gas Plasma has strong antimicrobial efficacy including MRSA and with a physical mode of action is unlikely to induce resistance. This alternative technology can help to combat antibiotic resistance. Gas plasma technology can also be used to deactivate microorganisms on surfaces and hard to clean areas in factories and laboratories.

Surface Treatment – Plasma processing may help to modify the surface of materials to enhance processing. Examples of potential applications include pre-treatment to enhance bonding, removal of contaminants from surfaces and modifying a surface to become hydrophobic or hydrophilic.

Our current product portfolio is available on our website www.adtec-rf.eu and we can offer expertise and know-how to develop plasma processing for a range of applications.

[adtecplasma-blog]

Adtec Healthcare congratulates the R&D Manager Takuya Urayama on receipt of the second place award for Most Innovative Product at JWC Awards 2017.

Takuya is design leader for the Adtec SteriPlas gas plasma device. He also leads the team for development of Adtec microwave gas plasma devices in other applications such as sanitisation of hard to clean areas in food factories and surface treatment.  

Adtec gas plasma was first developed in the Innovation department of our parent company in Japan. In collaboration with the Max Planck Institute, the gas plasma medical device was developed starting the first clinical trials of plasma on wounds worldwide.  The science of the mode of action of plasma, safety of the device and the clinical evidence of microbial load reduction were published by the scientific team.

Receipt of a Journal of Wound Care award is welcome recognition of the role of gas plasma in managing infections in wounds and surgical site infections. Adtec SteriPlas gas plasma has been adopted for standard care in treatment of wounds and surgical site infections in hospitals in Europe.  We look forward to continued support of innovation and gaining acceptance of alternative technologies to combat antibiotic resistance. 

[adtecplasma-blog]

Adtec SteriPlas plasma technology adopted by German hospital in treatment of Surgical Site Infections.

Adtec Healthcare is pleased to report on the successful qualification of Adtec SteriPlas gas plasma technology by a hospital in Germany. Following a successful evaluation on the use of Adtec gas plasma in the treatment of surgical site infections, a University Hospital has approved the purchase of an Adtec SteriPlas unit.

Adtec SteriPlas gas plasma is a topical antimicrobial that has been proven to reduce the microbial load on chronic wounds and surgical site infections with no side effects or adverse events reported.

Gas Plasma has the advantage that as a gas, it migrates to hard to treat areas that are difficult to manage with standard antimicrobial treatment such as antibiotics, antimicrobial dressings and antiseptics. The mode of action of gas plasma is physical and the bacteria are therefore unlikely to develop resistance. Gas Plasma also has proven clinical efficacy in deactivating antibiotic resistant bacteria such as MRSA etc.

Adtec plasma technology has also been successfully used to treat difficult to reach infections on the driveline entry of Ventricular Assist Devices (LVAD)  in cardiac patients and these results have been presented at EWMA May 2016 and WUWHS September 2016.

We look forward to collaborating with medical professionals in the qualification of Adtec SteriPlas as an approved treatment method for all types of surgical site infections.

[adtecplasma-blog]

Adtec receives second place award in the ‘Most Innovative Product’ Category in Journal of Wound Care awards

We are delighted to be awarded second place in the 'Most Innovative Product:' category at the Journal of Wound Care/ World Union of Wound Healing Societies awards. The results were announced at  the awards ceremony on Tuesday September 27th during the WUWHS congress in Florence.

Adtec first  introduced our cold plasma technology to the Max Planck Institute in 2004 which led to a joint collaboration in Plasma Medicine. Adtec non-thermal gas plasma technology is based on a microwave driven argon gas plasma.  We are indebted to the great scientists, researchers and medical professionals in the Plasma Medicine team including the Max Planck Institute, Schwabing and Regensburg hospitals and collaborating universities.   Adtec SteriPlas technology with over 9 years of clinical experience has proven antimicrobial efficacy, infection management and safety with no side effects reported. Gas Plasma with a physical mode of action is less likely to induce microbial resistance and can therefore be considered as a viable alternative to antibiotics in topical infections.

http://jwcworldunion.com/2016-winners/

We are also pleased to report the successful treatment of surgical site infections as presented by Dr Rotering of Universitätsklinik Münster at the WUWHS congress. Gas Plasma migrates to hard to reach areas to manage infection such as the driveline entry on VAD devices.  

The main advantages of using Adtec SteriPlas were reported by Dr Rotering as follows;

Increased penetration depth due to gaseous condition

Effectiveness independent to resistance profile

Possible treatment option to defeat biofilm

Good compatibility

Until now no contraindications are known

[adtecplasma-blog]

Adtec receive funding to conduct a clinical biofilm project in UK Hospital

Adtec Healthcare is delighted to announce that we will start a project to measure the ‘Efficacy of non-thermal gas plasma (NTGP) on sub-clinical wound infection (biofilm) in patients with diabetic foot ulcers’ in August 2016. The project will be a collaboration between Salford Royal NHS Foundation Trust, leading UK wound care experts, University Hospital Jena Germany and Adtec. The project is co-funded by the UK's Innovation agency, Innovate UK and Adtec.

Mary McGovern, Managing Director of Adtec said ‘We will work with leading experts to carry out a clinical evaluation of the efficacy of plasma on biofilms and qualify test methods to quantitatively measure the effect.  We are very excited to be working with a great group of people all sharing a passion for research and in making improvements in the treatment of wound infections’. 

Collaborators

Salford Royal NHS Foundation Trust – The podiatrists leading the project are Dr Paul Chadwick and Mrs Samantha Haycocks. Dr Paul Chadwick is a Consultant Podiatrist with over 25 years’ experience of podiatric care and Mrs Samantha Haycocks is an Advanced Research Podiatrist also with over 25 years’ experience in the same field.   The objective is to recruit and treat diabetic foot ulcer patients with NTGP at Salford and take samples for analysis.  The samples will then be sent to Jena for analysis.

Lt Col Professor Steven Jeffery – Professor at Birmingham City University and consultant surgeon at Queen Elizabeth hospital.  He specializes in the assessment and treatment of scarring, traumatic wounds and burns. Professor Jeffery is the chief scientific advisor for the project.

Mr Keith Cutting  (Clinical research Consultant) – Mr Cutting is an expert in wound care with over 130 peer reviewed publications  and his paper Criteria for wound Infection remains the most widely cited paper on clinical criteria of wound infection . Mr Cutting will be the clinical supervisor of the project providing guidance on the protocol and clinical project management.

Dr. Cornelia Wiegand, Department of Dermatology, University Hospital Jena, Germany. Dr Wiegand is a research scientist of wound care with particular interest in infection management and biofilms. Dr Wiegand will supervise the microbiology, biochemistry and histology analysis to measure the efficacy of plasma on biofilms.  

We are very grateful to be awarded funding from Innovate UK. We are confident that the project results will be of benefit in guidance for treatment of biofilms and in providing a better quality of life for patients.

[adtecplasma-blog]

Successful treatment of surgical site infections with Adtec SteriPlas

We are delighted to report that Adtec SteriPlas plasma technology has been successfully used to treat surgical site infections.

The results were presented by Dr Rotering, ‘New options for infection control in wound management’, at the European Wound Management Association (EWMA) conference, Bremen May 2016.   Dr Heinrich Rotering carried out the tests at the Universitätsklinik Münster, Germany and they plan to carry out more research on the use of plasma on surgical site infections. Some of the results have been added to a new case study on our website.

The possible advantages of using plasma to treat surgical site infections are

·         Increased penetration depth due to gaseous condition

·         Effectiveness independent to resistance profile

·         Possible treatment option to defeat biofilm

·         Good compatibility

·         Until now no contraindications are known

We plan to collaborate with research partners to produce more data on SSI management demonstrating that plasma could be considered as a viable alternative to antibiotics.

[adtecplasma-blog]

Adtec have a busy year ahead and will be exhibiting at the following events, be sure to come along and partake in live demos of our non-thermal gas plasma ‘SteriPlas’ device.

7th Annual Abu Dhabi Wound Care Conference 22nd – 23rd April 2016.

http://www.abudhabiwoundcare.com/

 European Wound Management Association (EWMA) and Deutscher Wundkongress in Bremen Germany on 11th- 13th May 2016. Hall 5, Stand 42.

http://ewma2016.org/

 5th Annual World Union of Wound Healing Societies (WUWHS) congress in Florence, Italy on 25th – 29th September 2016. Spadolini Pavilion, Stand 94.

http://www.wuwhs2016.com/

 The 12th German Congress of Orthopaedics and Trauma Surgery (DKOU) in Berlin, Germany 25th – 28th October 2016.

http://dkou.org/2016/international/home.html

[adtecplasma-blog]

Adtec Healthcare are exhibiting at the following events and look forward to seeing you there.

7th Joint Meeting of the European Tissue repair Society and the Wound Healing Society in Copenhagen, Denmark on 21st-23rd October, 2015

http://www.etrs-whs2015.org/

Wounds UK in Harrogate UK on 9th-11th November, 2015

http://www.wounds-uk.com/events.php?eventid=89

 ArabHealth in Dubai, UAE on 25th -28th January, 2016

http://www.arabhealthonline.com/

 EWMA and Deutscher Wundkongress in Bremen Germany on 11th-13th May 2016

http://www.ewma2016.org/

Adtec will be showcasing the new SteriPlas® Wound Management System with proven antimicrobial efficacy and safety over 7 years of clinical trials.